The proprietary combination adjuvants AS01 and AS04 are used in approved vaccines (Shingrix and Cervarix, respectively). Another successful adjuvant, GLA-SE, is currently in late-stage clinical trials. To make these classes of adjuvants available to vaccine developers, the contractor is developing functional mimics for low-cost and effective vaccines against emerging diseases and to address major health gaps worldwide.